Last reviewed · How we verify
Catapres-Tts-1 (CLONIDINE)
Catapres-TTS-1 (CLONIDINE) is a central alpha-2 adrenergic agonist, a small molecule drug developed by Boehringer Ingelheim and currently owned by Lavipharm. It targets the alpha-2A adrenergic receptor to treat various conditions, including attention deficit hyperactivity disorder, hypertension, and glaucoma. Approved in 1974, Catapres-TTS-1 has a bioavailability of 95% and a half-life of 7.6 hours. The drug is off-patent, with four generic manufacturers available. Key safety considerations include potential side effects such as dry mouth, dizziness, and sedation.
At a glance
| Generic name | CLONIDINE |
|---|---|
| Sponsor | Lavipharm |
| Drug class | Central alpha-2 Adrenergic Agonist |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Attention deficit hyperactivity disorder
- Hypertensive disorder
- Increased Intraocular Pressure after Ocular Procedure
- Open-angle glaucoma
- Severe pain
Common side effects
- drowsiness
- dry mouth
- dizziness
- constipation
- sedation
Drug interactions
- cyclobenzaprine
- desipramine
- doxepin
- imipramine
- metoprolol
- mirtazapine
- nadolol
- nortriptyline
- penbutolol
- pindolol
- propranolol
- protriptyline
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine (PHASE3)
- Premedication in Children: a Clinical Trial Comparing Oral Ketamine and Oral Clonidine With Respect to Sedation Level and Opioid Consumption in Pediatrics Undergoing Elective Lower Abdominal Day-case Surgery. (NA)
- Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (PHASE2)
- Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty (PHASE4)
- Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study (PHASE1)
- Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder (PHASE4)
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Patents
| Patent | Expiry | Type |
|---|---|---|
| 8337890 | 2027-04-17 | Formulation |
| 8623409 | 2031-09-08 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Catapres-Tts-1 CI brief — competitive landscape report
- Catapres-Tts-1 updates RSS · CI watch RSS
- Lavipharm portfolio CI